Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-OLE open-label extension of lerodalcibep in patients needing additional LDL-C lowering
MOH_2021-05-18_009979Phase 3Not yet recruiting
- Sponsor
- LIB Therapeutics, LLC
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lerodalcibep in familial hypercholesterolemia (FH) and hypercholesterolemia, sponsored by LIB Therapeutics, LLC. Primary endpoints: Long-term safety, Long-term tolerability and 1 more. Planned start May 2021; status: not yet recruiting.
02
Drugs
lerodalcibep
03
Conditions
familial hypercholesterolemia (FH)hypercholesterolemia
Beyond the preview
Go deeper on MOH_2021-05-18_009979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-18_009979.